As you will be aware, the Department for Health and Social Care has asked NICE to conduct a Single Technology Appraisal of binimetinib (as monotherapy) for treating NRAS mutant melanoma.
However, the company have now advised that they will not be pursuing a marketing authorisation application for binimetinib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes